Cambridge scientists have developed and tested a new drug in mice that has the potential to reduce damage to the brain when ...

Revalesio, a clinical-stage biopharmaceutical company developing treatments for acute and chronic neurological disorders, today announced that the U.S. Food and Drug Administration has granted Fast ...

DelveInsight’s, “Ischemic Stroke Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ ...

Stroke is the second leading cause of death globally. Ischemic stroke, strongly linked to atherosclerotic plaques, requires ...

A groundbreaking study from the University of Cambridge reveals a new drug that can significantly reduce brain damage caused ...

CHI Memorial is proud to announce it is the first hospital in the world to enroll a patient in a Phase 3 clinical trial evaluating a promising new treatment for ischemic stroke. This groundbreaking ...

DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic ...

UT Dell Medical School study helps solve question of when to start blood thinners after a stroke in someone with AFib.

At 7 days, mean systolic BP was 139.1 mm Hg in the early-treatment group compared with 150.9 mm Hg in the delayed-treatment group (net difference, 11.9 mm Hg; 95% CI 12.9 to 10.9; P < .0001).

Between June 20, 2019, and Nov. 16, 2021, 104 patients (median age, 73 years) were enrolled and randomly assigned within 4 to 5 hours of stroke symptom onset to receive 0.25 mg/kg tenecteplase as ...

The forward-looking statements and information in this press release include statements regarding the benefits of Fast Track Designation for DM199 for the treatment of acute ischemic stroke.

Exogenous inter-α inhibitor proteins prevent cell death and improve ischemic stroke outcomes in mice. Journal of Clinical Investigation, 2021; 131 (17) DOI: 10.1172/JCI144898 ...